Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2*

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 535-540

  Berchem, Guy J ^a,b   Bosseler, Manon ^a   Mine, Natacha ^a   Avalosse, Bernard ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b NONE   (Luxembourg)

Author keywords

Breast cancer; Cell cycle; Doxorubicin; Etoposide; Programmed cell death

Indexed keywords

DOCETAXEL; DOXORUBICIN; ETOPOSIDE; ONCOPROTEIN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE; CELL CYCLE G2 PHASE; CELL DEATH; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; ETOPOSIDE; FEMALE; FLOW CYTOMETRY; G2 PHASE; HUMANS; MITOSIS; PACLITAXEL; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; TAXOIDS; TUMOR CELLS, CULTURED;

EID: 0032922468     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Docetaxel monograph, Rhone Poulenc Roehrer http://interserv.rpr.rpna.com/HEALTH_MEDICINE/TAXOTERE/ ppi.html
2. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA, and Van Glabbeke M: Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer J Clin Oncol 13: 314-322, 1995.
3. Piccart M: Docetaxel: a new defence in the management of breast cancer. Anticancer Drugs 6 Suppl 4: 7-11, 1995.
4. Mamounas EP: NSABP Protocol B-27. Preoperative doxorubicin plus cyclophosphamide followed by preoperative or postoperative docetaxel. Oncology (Huntingt) 11: 37-40, 1997.
5. Bissery MC, Vrignaud P, and Lavelle F: Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination, Semin Oncol 22: 3-16, 1995.
6. Baker S: Drug interactions with taxanes, Pharmacotherapy 17: 126S-132S, 1997.
7. Holmes FA, Madden T, and Newman RA: Sequence dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer. J Clin Oncol 14: 2713-2721, 1996.
8. Haldar S, Jena N, and Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
9. Haldar S, Chintapalli J, and Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
10. Haldar S, Basu A, and Croce CM: Bcl-2 is the guardian of microtubule integrity. Cancer Res 57: 229-233, 1997.
11. Chen CY and Faller DV: Phosphorylation of Bcl-2 protein and association with p21Ras in Ras-induced apoptosis, J Biol Chem 271: 2376-2379, 1996.
12. May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, and Davidson NE: Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL2 alpha in association with suppression of apoptosis. J Biol Chem 269: 26865-26870, 1994.
13. Wang HG, Miyashita T, Takayama S, Sato T, Torigoe T, Krajewski S, Tanaka S, Hovey L, 3rd Troppmair J, Rapp UR and et al: Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase. Oncogene 9: 2751-2756, 1994.
14. Wang HG, Rapp UR, and Reed JC: Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87: 629-638, 1996.
15. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, and Neckers LM: Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway, Cancer Res 56: 1851-1854, 1996.
16. Blagosklonny MV, Giannakakou P, el-Deiry WS, Kingston DG, Higgs PI, Neckers L, and Fojo T: Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57: 130-135, 1997.
17. Schandl CA, Priest DG and Willingham MC: Phosphorylation of BCL-2 is a cell cycle-regulated event. Cell Pharmacol 3: 367-372, 1996.